Targeting spleen tyrosine kinase (SYK) in solid tumors

Spleen tyrosine kinase (SYK), a nonreceptor tyrosine kinase that is overexpressed in several solid tumors, presents a promising therapeutic target.

SYK activation downstream of various receptors drives signaling pathways that facilitate tumor progression and immune evasion.

SYK inhibition enhances the antitumor immune response in solid tumors by reprogramming myeloid and B cells or directly targeting tumor cells.

SYK inhibition can overcome resistance to chemotherapy and immunotherapy in solid tumors. Clinical trials targeting SYK in solid tumors are underway.

https://www.cell.com/trends/pharmacological-sciences/fulltext/S0165-6147(24)00168-8

https://sciencemission.ayurmatrika.com/New-insights-into-SYK-targeting-in-solid-tumors